Korean J Med.
2008 Feb;74(2):198-202.
A case of leptomeningeal metastasis from adenocarcinoma of the lung improved by treatment with Gefitinib
- Affiliations
-
- 1Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. jhchn@med.yu.ac.kr
Abstract
- Leptomeningeal metastasis occurs in approximately 1% of patients with non-small cell lung cancer and this is an extremely serious complication. Without treatment, the median survival of patients is 4~6 weeks. The treatment options currently available are limited and achieve only modest results. Gefitinib was recently approved for the treatment of advanced/refractory non-small cell lung cancer. In addition, there have been case reports showing activity of gefitinib against brain metastasis in non-small cell lung cancer patients. However, there is limited data on the ability of gefitinib to cross the blood-brain barrier. We report the case of a patient with leptomeningeal metastasis from adenocarcinoma of the lung that had a dramatic response to gefitinib treatment.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Analysis of Leptomeningeal Metastasis in Cerebrospinal Fluid Cytology
- Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma
- Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for patient with leptomeningeal metastasis of epidermal growth factor receptor mutant non-small cell lung cancer
- The Effectiveness of Gefitinib on Spinal Metastases of Lung Cancer: Report of Two Cases
- Chest Wall Pain as the Presenting Symptom of Leptomeningeal Carcinomatosis
